In contrast to this “CD4+ T scenario”, in mice immunized with PR_Ai3mut presenting the V82A mutation, the immune response was dominated by CD8+ T cells specific to T-cell epitope(s) at aa 76–90 recognizing the V82A mutation, which were able to prevent the growth and metastatic activity of tumor cells despite the comparatively low specific T-cell response. This evidence concerns the gene CD4 and neoplasm.